Pure Biologics S.A. is one of the largest Polish biotech companies. Founded in 2010, it is listed on the the Warsaw Stock Exchange.

Pure Biologics’ major R&D activity focuses on bispecific and fusion antibodies, as well as aptamers to be developed into viable candidates for therapeutics in immunooncology (colorectal, breast and lung cancers), and in the treatment of neurological diseases (neuromyelitis optica, myasthenia gravis).

To this end, Pure Biologics has created highly efficient platforms to generate specific antibodies and modified aptamers, supported by state-of-the-art assays and analytics.

Moreover, Pure Biologics utilizes its broad experience in antibodies, aptamers, cell and molecular biology, protein and antigen expression and purification, custom assay development, and ligand-binding analysis, offering complex solutions not only as a contract research organization and service provider, but primarily as a professional consultant and R&D partner. Its customers represent a wide variety of environments, ranging from academic collaborations to pharma and biotech companies.

Pure Biologics aims to out-license its early-stage assets and to connect with partners in need of complex biotechnological solutions.